{"id":"s-1-plus-cddp","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Stomatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"S-1 is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase, disrupting DNA synthesis. CDDP (cisplatin) is a platinum-based agent that forms DNA adducts and cross-links, preventing DNA replication and transcription. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"S-1 plus CDDP is a combination chemotherapy regimen that inhibits thymidylate synthase and causes DNA cross-linking to suppress cancer cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:08.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer"},{"name":"Gastroesophageal junction cancer"},{"name":"Esophageal cancer"}]},"trialDetails":[{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":"Biliary Tract Cancer","enrollment":142},{"nctId":"NCT06109779","phase":"PHASE3","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-04","conditions":"Biliary Tract Cancer","enrollment":757},{"nctId":"NCT05535166","phase":"PHASE2","title":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-12-20","conditions":"Medulloblastoma","enrollment":130},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT01878617","phase":"PHASE2","title":"A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-23","conditions":"Medulloblastoma","enrollment":660},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT07088484","phase":"","title":"Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-01","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT07085234","phase":"PHASE2","title":"Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-07-30","conditions":"Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy, Induction Therapy","enrollment":30},{"nctId":"NCT07080437","phase":"","title":"An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Three Gorges Hospital of Chongqing University","startDate":"2021-03-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":40},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT06811844","phase":"PHASE2","title":"Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-02-25","conditions":"Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy","enrollment":208},{"nctId":"NCT03645928","phase":"PHASE2","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2019-05-07","conditions":"Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer","enrollment":245},{"nctId":"NCT03406299","phase":"PHASE2","title":"Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-04-19","conditions":"Biliary Tract Neoplasms","enrollment":92},{"nctId":"NCT06422858","phase":"PHASE2","title":"Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-05-20","conditions":"Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma","enrollment":37},{"nctId":"NCT06903273","phase":"PHASE2","title":"Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"National Cheng-Kung University Hospital","startDate":"2025-07-01","conditions":"Cholangiocarcinoma, Biliary Tract Cancer (BTC)","enrollment":35},{"nctId":"NCT06730373","phase":"PHASE2","title":"First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-10-17","conditions":"HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma","enrollment":110},{"nctId":"NCT01286766","phase":"PHASE2","title":"Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":6},{"nctId":"NCT03814759","phase":"PHASE2","title":"Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-12-12","conditions":"Gastric Adenocarcinoma","enrollment":102},{"nctId":"NCT01285557","phase":"PHASE3","title":"Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2011-04-14","conditions":"Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction","enrollment":361},{"nctId":"NCT00400179","phase":"PHASE3","title":"A Safety and Efficacy Study in Patients With Gastric Cancer","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2005-05","conditions":"Gastric Cancer","enrollment":1053},{"nctId":"NCT00398307","phase":"PHASE1","title":"Evaluating Patients With Varying Degrees of Renal Function","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2006-02","conditions":"Renal Impairment","enrollment":24},{"nctId":"NCT00398424","phase":"PHASE1","title":"Evaluating Patients With Impaired Hepatic Function","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2006-02","conditions":"Impaired Hepatic Function","enrollment":24},{"nctId":"NCT00072787","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2003-10","conditions":"Gastric Cancer","enrollment":41},{"nctId":"NCT00651833","phase":"PHASE2","title":"Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2005-02","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT02995850","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2017-02-22","conditions":"Gastric Cancer With Peritoneal Metastasis (PCI<12)","enrollment":25},{"nctId":"NCT03769935","phase":"PHASE2","title":"Maintenance Therapy for Small-cell Lung Cancer","status":"COMPLETED","sponsor":"Qingdao Central Hospital","startDate":"2017-01-01","conditions":"Progression Free Survival","enrollment":90},{"nctId":"NCT05497739","phase":"PHASE2","title":"Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-06-28","conditions":"Gastric Cancer","enrollment":68},{"nctId":"NCT03946969","phase":"PHASE2","title":"Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2019-05-09","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT03617133","phase":"PHASE2","title":"Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2016-04","conditions":"Uterine Cervical Neoplasms","enrollment":1000},{"nctId":"NCT02322593","phase":"PHASE3","title":"Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2014-12","conditions":"Gastric Cancer","enrollment":711},{"nctId":"NCT03051373","phase":"PHASE2","title":"Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2017-04-01","conditions":"Carcinoma, Transitional Cell","enrollment":108},{"nctId":"NCT02128243","phase":"PHASE2","title":"Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-09","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma","enrollment":242},{"nctId":"NCT02862535","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-09-20","conditions":"Gastric Adenocarcinoma","enrollment":36},{"nctId":"NCT02114359","phase":"PHASE3","title":"Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-02","conditions":"Gastric Cancer","enrollment":111},{"nctId":"NCT04465968","phase":"PHASE3","title":"Efficacy and Safety of CRT, Durvalumab and Surgery for SST","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2020-09-01","conditions":"Superior Sulcus Tumor, Non-small Cell Lung Cancer Stage IIB, Non Small Cell Lung Cancer Stage III","enrollment":84},{"nctId":"NCT02495493","phase":"PHASE2","title":"S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2013-07","conditions":"Gastric Adenocarcinoma","enrollment":42},{"nctId":"NCT00915382","phase":"PHASE3","title":"Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer: SOS","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2009-01","conditions":"Advanced Gastric Cancer","enrollment":625},{"nctId":"NCT00806117","phase":"PHASE3","title":"Comparison of Different Subsequent Treatments After Radical Surgery","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2008-02-25","conditions":"Cervical Cancer","enrollment":1080},{"nctId":"NCT00770874","phase":"PHASE3","title":"Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2008-09","conditions":"Cervical Cancer","enrollment":375},{"nctId":"NCT02182778","phase":"PHASE3","title":"GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2014-07-09","conditions":"Biliary Tract Cancer","enrollment":246},{"nctId":"NCT01821248","phase":"PHASE2","title":"A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis","status":"UNKNOWN","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2013-07-23","conditions":"Biliary Tract Cancer","enrollment":25},{"nctId":"NCT03825328","phase":"PHASE2","title":"A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )","status":"UNKNOWN","sponsor":"Yanqiao Zhang","startDate":"2019-01-30","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT01283204","phase":"PHASE2","title":"Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-03-09","conditions":"Recurrent or Metastatic Gastric Cancer","enrollment":180},{"nctId":"NCT01783951","phase":"PHASE1, PHASE2","title":"Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2013-02-01","conditions":"Gastric Cancer","enrollment":63},{"nctId":"NCT02359058","phase":"PHASE1","title":"A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-02","conditions":"Stomach Neoplasms","enrollment":18},{"nctId":"NCT03061058","phase":"PHASE3","title":"Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2013-04-01","conditions":"Stomach Neoplasms, Chemotherapy Effect, Chemotherapeutic Toxicity","enrollment":240},{"nctId":"NCT02913066","phase":"PHASE2","title":"S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Mianyang Central Hospital","startDate":"2016-09","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":88},{"nctId":"NCT03179579","phase":"PHASE3","title":"Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer","status":"UNKNOWN","sponsor":"Shu-Zhong Cui","startDate":"2017-08-01","conditions":"Gastric Cancer, Peritoneal Carcinomatosis","enrollment":88},{"nctId":"NCT01704690","phase":"PHASE2, PHASE3","title":"Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer","status":"TERMINATED","sponsor":"Peking University","startDate":"2012-08","conditions":"Esophageal Cancer","enrollment":4},{"nctId":"NCT02878889","phase":"PHASE2","title":"A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2016-08","conditions":"Nasopharyngeal Carcinoma","enrollment":53},{"nctId":"NCT00252161","phase":"PHASE3","title":"A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer","status":"COMPLETED","sponsor":"Haruhiko Fukuda","startDate":"2005-11","conditions":"Gastric Neoplasm","enrollment":316},{"nctId":"NCT00142350","phase":"PHASE3","title":"A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Japan Clinical Oncology Group","startDate":"2000-11","conditions":"Gastric Cancer","enrollment":690},{"nctId":"NCT01854749","phase":"PHASE2","title":"S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study","status":"COMPLETED","sponsor":"Fudan University","startDate":"2011-11","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":57},{"nctId":"NCT02677597","phase":"PHASE3","title":"Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2016-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":268},{"nctId":"NCT01671449","phase":"PHASE3","title":"S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Min-Hee Ryu","startDate":"2012-12","conditions":"Gastric Cancer","enrollment":338},{"nctId":"NCT02586753","phase":"PHASE2","title":"Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus","status":"UNKNOWN","sponsor":"Mianyang Central Hospital","startDate":"2015-12","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":2},{"nctId":"NCT01679340","phase":"PHASE2","title":"A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery","status":"UNKNOWN","sponsor":"Peking University","startDate":"2011-04","conditions":"Gastric Cancer","enrollment":160},{"nctId":"NCT02396498","phase":"PHASE3","title":"SP Intravenous Chemotherapy Versus SP by HIPEC in Stage Ⅲ Patients After D2 Gastrectomy","status":"UNKNOWN","sponsor":"Tang-Du Hospital","startDate":"2014-04","conditions":"Stage Ⅲ Gastric Cancer","enrollment":270},{"nctId":"NCT00553696","phase":"PHASE1","title":"Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11","conditions":"Stomach Neoplasms","enrollment":27},{"nctId":"NCT02370849","phase":"PHASE2","title":"Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2009-10","conditions":"Stomach Neoplasms","enrollment":2},{"nctId":"NCT02291211","phase":"PHASE2","title":"S-1 Combined Cisplatin HIPEC for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis","status":"UNKNOWN","sponsor":"Tang-Du Hospital","startDate":"2014-09","conditions":"Stage IV Gastric Cancer","enrollment":60},{"nctId":"NCT02223611","phase":"PHASE2","title":"Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection","status":"UNKNOWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2014-12","conditions":"Non-small Cell Lung Cancer Stage Ⅱ, Non-small Cell Lung Cancer Stage ⅢA","enrollment":100},{"nctId":"NCT01284413","phase":"PHASE1, PHASE2","title":"Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2010-12","conditions":"Biliary Tract Cancer","enrollment":68},{"nctId":"NCT01388790","phase":"PHASE2","title":"Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-06","conditions":"Gastric Cancer","enrollment":40},{"nctId":"NCT00088816","phase":"PHASE2","title":"S-1 and Cisplatin Before Surgery in Treating Patients With Stage IV Gastric Cancer","status":"UNKNOWN","sponsor":"Kyoto University","startDate":"2003-04","conditions":"Gastric Cancer","enrollment":50},{"nctId":"NCT00182611","phase":"PHASE3","title":"S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer","status":"COMPLETED","sponsor":"Kyoto University","startDate":"2004-04","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT01736410","phase":"PHASE2","title":"A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2010-05","conditions":"HER 2 Positive Advanced Gastric Cancer","enrollment":30},{"nctId":"NCT00663741","phase":"PHASE1","title":"Sorafenib Gastric Cancer Asian Phase I Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-05","conditions":"Gastric Cancer","enrollment":13},{"nctId":"NCT01283217","phase":"PHASE3","title":"Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2010-03","conditions":"Gastric Adenocarcinoma","enrollment":166},{"nctId":"NCT01824004","phase":"PHASE2","title":"Postoperative Chemoradiotherapy With S-1 in Gastric Cancer","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2009-04","conditions":"Gastric Cancer","enrollment":46},{"nctId":"NCT01747707","phase":"PHASE2","title":"Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2012-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":40},{"nctId":"NCT01645748","phase":"PHASE2","title":"Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2008-10","conditions":"Head and Neck Cancer","enrollment":35},{"nctId":"NCT01426646","phase":"PHASE2","title":"S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy to Treat Gastric Cancer","status":"UNKNOWN","sponsor":"Kyungpook National University Hospital","startDate":"2011-09","conditions":"Gastric Cancer","enrollment":218},{"nctId":"NCT00659113","phase":"PHASE2","title":"S-1, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIA, Stage III, or Stage IVA Esophageal Cancer That Can Be Removed by Surgery","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2008-03","conditions":"Esophageal Cancer","enrollment":32},{"nctId":"NCT01375972","phase":"PHASE2","title":"Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2008-03","conditions":"Metastatic Biliary Cancer","enrollment":92},{"nctId":"NCT01198392","phase":"PHASE3","title":"Trial of S-1 Plus Cisplatin in Gastric Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2008-09","conditions":"Gastric Cancer","enrollment":270},{"nctId":"NCT00202969","phase":"PHASE3","title":"Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2005-07","conditions":"Gastric Cancer","enrollment":180},{"nctId":"NCT00960349","phase":"PHASE1","title":"Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Gastric Cancer","enrollment":14},{"nctId":"NCT00625937","phase":"PHASE2","title":"Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2006-11","conditions":"Head and Neck Cancer","enrollment":46},{"nctId":"NCT00874328","phase":"PHASE1, PHASE2","title":"A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2008-10","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":74},{"nctId":"NCT00980603","phase":"PHASE2","title":"Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2008-11","conditions":"Gastric Cancer","enrollment":144}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":197,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"S-1 plus CDDP","genericName":"S-1 plus CDDP","companyName":"Taiho Pharmaceutical Co., Ltd.","companyId":"taiho-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"S-1 plus CDDP is a combination chemotherapy regimen that inhibits thymidylate synthase and causes DNA cross-linking to suppress cancer cell proliferation. Used for Gastric cancer, Gastroesophageal junction cancer, Esophageal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}